Skip to main content

Table 2 Head-to-head comparisons of treatment pattern and tumor response between the propensity score matched treatment groups

From: Clinical effectiveness and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced non-squamous non-small cell lung cancer in Chinese patients: a retrospective cohort study

Comparison Platinum/Pemetrexed vs. Platinum/Docetaxel    Platinum/Pemetrexed vs. Platinum/Paclitaxel    Platinum/Pemetrexed vs. Platinum/Gemcitabine    Platinum/Pemetrexed vs. Platinum/Vinorelbine   
Matched pairs 95 RR P value* 118 RR P value* 199 RR P value* 72 RR P value*
Measured outcomes N Mean/% STDEV N Mean/% STDEV    N Mean/% STDEV N Mean/% STDEV    N Mean/% STDEV N Mean/% STDEV    N Mean/% STDEV N Mean/% STDEV   
Treatment pattern                                 
Completed treatment cycles 95 3.4 1.7   95 2.9 1.7 0.028 118 3.6 1.7 118 2.9 1.6   0.006 199 3.6 1.7 199 2.7 1.5   <0.001 72 3.3 1.7 72 2.5 1.3   0.003
Length of hospital stay per cycle (days) 95 10.1 6.7 95 11.5 8.2   0.191 118 10.4 6.1 118 13.5 11.7   0.011 199 10.9 6.0 199 15.0 7.0   <0.001 72 13.1 7.2 72 16.9 8.5   0.001
Tumor response based on RECIST (%)                                 
PR 13 13.7%   13 13.7%   1.000 1.000 22 18.6%   6 5.1%   3.647 0.002 36 18.1%   18 9.1%   1.989 0.007 16 22.2%   9 12.5%   1.776 0.108
SD 44 46.3%   29 30.5%   1.518 0.025 45 38.1%   32 27.1%   1.406 0.074 72 36.2%   52 26.1%   1.387 0.043 28 38.9%   18 25.0%   1.556 0.077
PD 9 9.5%   13 13.7%   0.693 0.371 11 9.3%   21 17.8%   0.522 0.059 24 12.1%   23 11.6%   1.043 0.879 7 9.7%   12 16.7%   0.581 0.197
Unknown 29 30.5%   40 42.1%   0.724 0.101 40 33.9%   59 50.0%   0.678 0.020 67 33.7%   106 53.3%   0.632 <0.001 21 29.2%   33 45.8%   0.638 0.029
Other tumor response outcomes (%)                                 
Early treatment discontinuation 45 47.4%   62 65.3%   0.726 0.007 52 44.1%   71 60.2%   0.732 0.022 91 45.7%   135 67.8%   0.674 <0.001 38 52.8%   55 76.4%   0.691 0.007
Tumor control 57 60.0%   42 44.2%   1.357 0.029 67 56.8%   38 32.2%   1.764 <0.001 108 54.3%   70 35.2%   1.543 <0.001 44 61.1%   20 27.5%   2.222 0.005
Treatment failure 38 40.0%   53 55.8%   0.717 0.029 51 43.2%   80 67.8%   0.637 <0.001 91 45.7%   129 64.8%   0.705 <0.001 28 38.9%   45 72.5% 0.537   0.005
  1. STDEV, standard deviation; RR, rate ratio; RECIST, Response Evaluation Criteria in Solid Tumors; PR, partial response; SD, stable disease; PD, progressive disease. *: P values less than 0.05 were in bold to indicate significant differences.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us